| Annandale Care Center | |
| 500 Park Street East, Annandale, Minnesota 55302 | |
| (320) 274-3737 | |
| Name | Annandale Care Center |
|---|---|
| Location | 500 Park Street East, Annandale, Minnesota |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 60 |
| Occupancy Rate | 47.67% |
| Medicare ID (CCN) | 245364 |
| Legal Business Name | Annandale Care Center |
| Ownership Type | Non Profit - Corporation |
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
A new drug designed to "seek and destroy" common cancers such as breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers is being tested at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it was expanding its Phase 2 clinical trial of STA-9090 in patients with Stage IIIB and Stage IV non-small cell lung cancer (NSCLC) from up to 69 patients to up to 146 patients based on encouraging activity observed in the first stage of the two stage clinical trial.
New results from the world's biggest ovarian cancer screening trial led by UCL suggest that screening based on an annual blood test may help reduce the number of women dying from the disease by around 20%.
University of Calgary researcher Paul Kubes, PhD, is the recipient of one of Canada's top awards for medical research. An internationally-recognized scientist specializing in visualizing the mammalian immune system, Kubes will accept the 2011 Canada's Health Researcher of the Year award from the Canadian Institutes of Health Research (CIHR) at a ceremony in Ottawa this evening.
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 23.14 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 6.4 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 40.38 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.93 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.17 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 7.75 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 4.2 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 95.1 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 11.45 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 76.64 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 3.39 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 21.39 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 13.95 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 3.45 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.65 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 72.46 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 88.34 | 82.93 |
News Archive
A new drug designed to "seek and destroy" common cancers such as breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers is being tested at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it was expanding its Phase 2 clinical trial of STA-9090 in patients with Stage IIIB and Stage IV non-small cell lung cancer (NSCLC) from up to 69 patients to up to 146 patients based on encouraging activity observed in the first stage of the two stage clinical trial.
New results from the world's biggest ovarian cancer screening trial led by UCL suggest that screening based on an annual blood test may help reduce the number of women dying from the disease by around 20%.
University of Calgary researcher Paul Kubes, PhD, is the recipient of one of Canada's top awards for medical research. An internationally-recognized scientist specializing in visualizing the mammalian immune system, Kubes will accept the 2011 Canada's Health Researcher of the Year award from the Canadian Institutes of Health Research (CIHR) at a ceremony in Ottawa this evening.
› Verified 5 days ago
Annandale Care Center Location: 500 Park Street East, Annandale, Minnesota 55302 Phone: (320) 274-3737 |